Document:

Exhibit
10.3

 

Short-Term Incentive Plan

Deferred Stock Unit Plan Summary

 

In an effort to help our STIP participants increase their ownership in
Tennant stock, we have developed a plan which allows them the option to
exchange their cash award for deferred stock units.  The plan works as follows:

 

Deferred Stock
Unit Election

 

Prior to the beginning of
a plan year, an eligible participant can elect to convert all or a portion (in
10% increments) of the upcoming years STIP cash incentive award to deferred stock
units.

 

For each $1.00 of STIP
cash payment, participants will receive $1.20 in deferred stock units.

 

Deferred Stock
Unit Calculation

 

The deferred stock unit
account will be calculated as follows:

 

Annual STIP Award X Deferred
Stock Unit Election X 120% Conversion / Fair Market Value Closing Stock Price
on the Effective Date of the Grant

 

	
  Example:

  	
  STIP Award:
  $15,000

  
	
   

  	
  Deferred Stock
  Unit Election: 100% in Deferred Stock Units

  
	
   

  	
  Fair Market
  Value Stock Price: $33.00

  

 

$15,000
X 100% X 120% / $33.00 = 545 Stock Units*

 

*Rounded down to nearest
unit.

 

Deferred Stock
Unit Dividend Adjustments

 

In the event the Company
pays dividends on its common stock, additional deferred stock units will be
credited to a participant’s account effective as of the dividend payment date
based on the following calculation:

 

The number of Deferred stock
units in a participant’s account is multiplied by the dollar amount of the cash
dividend per share of common stock and then divided by the fair market value of
the stock as of the dividend payment date

 

Vesting

 

The 20% premium, of the
deferred stock units, will vest three years from the date of the award.

 

 

Payment of
Deferred Stock Unit Account

 

At the time of payment, a
participant’s deferred stock unit account will be paid in 50% stock and 50%
cash to cover applicable taxes.  To
calculate the cash value of the account, the number of deferred stock units
will be multiplied by the fair market value closing stock price at payment
date.

 

Termination
Provisions

 

If a participant
terminates employment with the Company prior to the vesting period, except by
reason of death, disability, or retirement, he/she will receive the equivalent
cash incentive award less the 20% deferred stock unit adjustment and any
dividend adjustments.

 

If a participant
terminates employment with the Company prior to the vesting period by reason of
death, disability, or retirement, he/she will receive payment of the account in
50% stock and 50% cash which will include a prorated amount of the 20% premium based
on the length of time employed with the Company during the three-year vesting
period.

 

Plan
Administration

 

Stock being distributed
through STIP deferred stock units will be issued and governed by the terms of
the 1999 Stock Incentive Plan.Exhibit 10(q)

 

HICKORYTECH
CORPORATION

 

Long-Term
Executive Incentive Program Summary

 

Purpose

This long-term incentive program ensures alignment between executive
actions and HickoryTech’s long-term strategic plan.  It is designed to drive shareholder value
through alignment of executive pay with corporate strategic goals.

 

Eligible
HickoryTech Employees

President/CEO

Division Presidents

CFO

Vice President of Human Resources

 

Executives in these positions whose employment begins after the start
of a Program period will be eligible for a prorated award based on the date of
hire or promotion to such position.

 

Eligible executives whose status as a participant ends prior to the end
of a Program period, for any reason other than retirement or death, will lose eligibility
for payouts under the Program.  Eligible
executives who leave HickoryTech’s employment for any reason other than
retirement or death will lose any unvested restricted stock.

 

Administration

The Program is administered by the Compensation Committee of the
HickoryTech Board of Directors.

 

Program
Provisions

The Long-Term Executive Incentive Program provides for restricted
shares to be granted to eligible participants if pre-established strategic
objectives are achieved.   These
strategic objectives are to be achieved over a two or three year performance
period.  If the objectives are not
obtained, no award will be granted.

 

The Program will have overlapping performance periods which will allow
the two or three year Programs to run concurrently.

 

Awards granted under this Program will be restricted stock.  One-half of the restricted shares will vest
30 days after grant, and the remaining one-half will vest on the first
anniversary of the grant.

 

The number of restricted shares to be granted will be determined at the
end of the performance period, based on the level of achievement of the
objectives, using linear interpolation between the performance levels of
Threshold (75% performance achievement), Target (100% performance achievement)
and Maximum (125% performance achievement).

 

An award range for the grant of restricted shares has been established
for each eligible position, if the pre-established objectives are achieved.

 

Share
Authorization

Shares utilized for this Program are granted under the 1993 Stock Award
Plan.  This Plan was authorized by
shareholders in 1993 and an amendment to this Plan was authorized by
shareholders in 2000.EXHIBIT 10.26

                              SETTLEMENT AGREEMENT

THIS  AGREEMENT,  entered into and effective as of the latest date  indicated in
the signature block at the foot of this Agreement,  is by and between Lifestream
Technologies,  Inc.  ("Lifestream"),  a Nevada  corporation  with a post  office
address at 510 Clearwater Loop, Suite 101; Post Falls,  Idaho 83854; and Polymer
Technology Systems, Inc. ("Polymer"),  an Indiana corporation with a post office
address 7736 Zionsville Road, Indianapolis, Indiana 46268.

                                   BACKGROUND

WHEREAS  Polymer and  Lifestream are parties to patent  infringement  litigation
Civil Action No.  CIV00-0300-N-MHW  presently  stayed  before the United  States
District Court for the District of Idaho,  which had entered a Judgment to which
the parties stipulated in favor of Polymer;

         WHEREAS the United  States  Court of Appeal for the Federal  Circuit in
Appeal No. 03-1630 on August 25, 2004  reversed-in-part and affirmed-in-part the
district court's claim construction, vacated the judgment of noninfringement and
remanded the case for further  findings to determine  whether Polymer  infringes
claim 1 of United States Patent No.  5,135,716  ("716 Patent") under the correct
claim construction;

         WHEREAS the stay ordered by the  District  Court is scheduled to expire
sixty (60) days following the entry of the Order by the Court of Appeals; and

         WHEREAS,  the parties are desirous of bringing the litigation to an end
under mutually agreeable terms;

         NOW  THEREFORE,  in  consideration  of the  performance  by each of the
parties-of  the terms set forth  herein,  the parties  hereto,  intending  to be
legally bound, mutually agree as follows:

                               TERMS OF AGREEMENT

         I. DISMISSAL OF LITIGATION

         1.1 The parties will file a stipulation of dismissal,  With  Prejudice,
and with each party to bear its own costs,  of all claims and  counterclaims  in
Civil Action No.  CIV00-0300-N-MHW  pursuant to Federal Rules of Civil Procedure

<PAGE>

41  without  any  statement  regarding  whether  the  '716  patent  is  valid or
infringed,  and  without  the  entry  of a  Settlement  Agreement  or any  other
commentary into the court record.

         1.2 Neither  party will receive any  compensation  from the other party
concerning activities occurring prior to this Agreement.

         II. License

         2.1 Lifestream  hereby grants Polymer a non-exclusive,  non-terminable,
non-transferable, non-sub-licensable (except to parties who manufacture products
for Polymer) License under the 716 Patent (the "License").

         2.2 The  parties  will  negotiate  in good  faith to  reach a  mutually
acceptable original equipment manufacturer (OEM) dry chemistry test strip supply
agreement that will (a) govern the products,  prices, payment terms, and related
considerations under which Polymer will become an OEM for Lifestream,  and which
(b) will  address how Polymer  will for limited  periods sell its HDL test strip
products ("HDL Products")  other than its lipid panel products,  with reasonable
protections  for Lifestream in the retail store  over-the-counter  market in the
United States ("OTC"). The Parties acknowledge that Internet-based sales are not
part of OTC.

         2.3 In the event that the parties do not  ultimately  enter into an OEM
agreement for any reason,  or if after entering into such  agreement  Lifestream
terminates  for any reason,  the License will become a fully paid,  unencumbered
License in all markets effective after December 31, 2007

         2.4 This Agreement will automatically  terminate upon expiration of the
716  Patent,   a  final,   non-appealable   judgment   that  it  is  invalid  or
unenforceable, or such other time as mutually agreed by the parties.

         III. Royalties and Payments

         3.1 Polymer will pay Lifestream a Royalty equal to [_______($___)]* per
each dry chemistry HDL Products test strip sold in the OTC market on or

----------
* Information has been redacted and is the subject of a request for Confidential
Treatment filed with the SEC.

                                        2

<PAGE>

after the date of this Agreement provided,  however,  that the  [_______($___)]*
per  strip  rate  shall  only  apply   while  the  market   price   stays  above
[_______($___)]* per strip. If the market price falls below [_______($___)]* per
strip, the Royalty rate will be reduced to [_________($___)]* per strip.

         The  parties   acknowledge  that  a  test  strip  that  measures  total
cholesterol,  of which a fraction is HDL, but does not measure HDL independently
is not  considered an HDL Product.  The parties  acknowledge  that a test strip,
such as a full lipid panel test strip,  that  measures HDL  independently  along
with other blood components is an HDL Product.

         3.2 The Royalty will not apply to HDL Products sold by Polymer  outside
the OTC market, nor to Polymer's sales, if any, to Lifestream.

         3.3 The Royalty will not apply to Polymer's  full lipid panel  products
OTC sales after December 31, 2005.

         3.4 Royalty  Payments  under this  Agreement  will be based on revenues
actually  received by Polymer,  will be computed on a calendar  quarterly basis,
and will be due and payable to Lifestream thirty (30) days after the end of each
quarter  for  revenues  actually  received  by Polymer  during  the  immediately
preceding  calendar quarter.  A final Royalty Payment will be due and payable to
Lifestream thirty (30) days after termination of this Agreement.

         3.5  Polymer  will keep  appropriate  accounting  records  of  revenues
actually received from OTC sales of HDL Products.

         3.6 Polymer will accompany each Royalty  Payment with a written Royalty
Report  stating the revenues  received by Polymer from OTC sales of HDL Products
and showing the computation of the Royalty Payment.

         3.7 If Polymer OTC sales of HDL  Products  subject to Royalty  Payments
during a particular  quarter result in a Royalty  Payment  obligation of $100 or
less, then Polymer need not provide Lifestream with a Royalty Report.

         3.8 Lifestream  will have the right to reasonably  audit the records of
Polymer  supporting the computation of the Royalty  Payments.  In the event that
any audit reveals an underpayment of any Royalty Payment of ten percent (10%)

----------
* Information has been redacted and is the subject of a request for Confidential
Treatment filed with the SEC.

                                        3

<PAGE>

or more, then Polymer will reimburse Lifestream the actual, out-of-pocket costs
associated with the audit.

         IV. MANUFACTURE AND MARKETING

         4.1 Lifestream will have no responsibilities, obligations, or rights in
the Polymer  intellectual  property  relating to the  manufacture or sale of HDL
Products

         4.2 Polymer will affix appropriate patent markings  identifying the 716
Patent pursuant to 35 U.S.C.  ss. 287 (a) to HDL Products sold by Polymer in the
United States during the term of this Agreement.

         V. PATENT PROSECUTION AND ENFORCEMENT

         5.1 Lifestream will have the exclusive  right to maintain,  enforce and
defend the 716 Patent at its sole  discretion.  Polymer shall not be required to
pay costs or expenses of any kind incurred directly or indirectly by Lifestream,
including  attorney and expert witness fees, in connection  with any enforcement
or defense of the 716 Patent.

         5.2 Polymer will promptly notify  Lifestream if it becomes aware of any
entity that appears to be likely infringing the 716 Patent.

         5.3 In the event of legal action concerning the 716 Patent,  each party
will provide  reasonable  assistance to the other party in  connection  with the
legal action.

         5.4 Neither party will be required by this  Agreement to become a party
to any dispute or litigation of any kind with third parties.

         VI. WARRANTIES AND INDEMNITIES

         6.1 Lifestream warrants that it is the owner of the 716 Patent, that it
has  paid all fees  required  to  maintain  the 716  Patent,  and that it has an
unencumbered  legal  right  to  enter  into  and  perform  as  required  by this
Agreement.

         6.2 Polymer  warrants that it has an unencumbered  legal right to enter
into and perform as required by this Agreement.

                                        4

<PAGE>

         6.3 LIFESTREAM  MAKES NO  REPRESENTATION  OR WARRANTY OF ANY KIND AS TO
THE VALIDITY OF THE 716 PATENT,  WHETHER A LICENSED  PRODUCT  INFRINGES  THE 716
PATENT, WHETHER A LICENSED PRODUCT DOES OR DOES NOT INFRINGE ANY PATENT, UTILITY
MODEL, OR OTHER RIGHT OF ANY THIRD PARTY,  WHETHER ANY PRODUCT  DESCRIBED IN THE
716 PATENT IS  FUNCTIONAL  FOR ANY  INTENDED  PURPOSE,  OR WHETHER  ANY  PRODUCT
DESCRIBED IN THE 716 PATENT 1S MERCHANTABLE.

         6.4 Notwithstanding the provisions of paragraph 6.3, above,  Lifestream
will  indemnify  and hold Polymer  harmless  from all loss,  cost,  and expense,
including  reasonable  attorney and witness fees, it incurs in responding to any
claim, demand, discovery request, subpoena, action, re-examination,  or the like
which is asserted by a third party concerning the validity or  enforceability of
the 716 Patent in whole or in part; provided, however, that Polymer will provide
Lifestream  with  reasonable  notice of such an event and afford  Lifestream  an
opportunity to avoid or handle such event itself,  in whole or in part, prior to
incurring any reasonably  avoidable  expense that  Lifestream is responsible for
under this paragraph. For the avoidance of doubt, "reasonably avoidable expense"
does not include  expenses,  by way of illustration and without  limitation,  in
connection with responses to written demands, complaints,  summonses,  subpoenas
or the like with  deadlines  of thirty (30) days or less from actual  receipt by
Polymer.

         6.5  Polymer  indemnifies,   holds  harmless,   and  agrees  to  defend
Lifestream with respect to any claim or cause of action arising out of Polymer's
manufacture,  use, sale or importation of products licensed under this Agreement
including, without limitation,  personal injury to persons using or misusing the
licensed  products  except  to the  extent  that any  such  matter  involves  an
assertion  of the validity or  enforceability,  of the 716 Patent in whole or in
part.

         6.6  Polymer  indemnifies,   holds  harmless,   and  agrees  to  defend
Lifestream  with respect to any right,  claim or cause of action  arising out of
Polymer's sublicensing of its rights under this Agreement except to the extent

                                        5

<PAGE>

that any such matter involves an assertion of the validity or enforceability of
the 716 Patent in whole or in part.

         VII. MISCELLANEOUS

         7.1  All  written  notices,  correspondence  and  payments  under  this
Agreement  will be delivered to the  addresses  of record first  written  above.
Either party may change its address of record with written notice.

         7.2 This Agreement constitutes the entire agreement between the parties
with respect to the subject  matter hereof,  supersedes all previous  express or
implied promises or understandings  related to the subject matter of hereof, and
may not be  varied,  amended,  or  supplemented  except by a writing  of even or
subsequent  date executed by both parties and  containing  express  reference to
this Agreement.

         7.3 The  failure  of  either  party to  enforce  at any time any of the
provisions of this Agreement,  or any rights in respect thereto,  will in no way
be considered a waiver of such provisions,  rights, or elections with respect to
subsequent events or in any way to affect the validity and the enforceability of
this Agreement.

         7.4 In the event  that any  provision  of this  Agreement  is  declared
invalid or legally unenforceable by a court of competent jurisdiction from which
no appeal is or can be taken, the invalid provision will be deemed replaced by a
similar but valid and  legally  enforceable  provision  as near in effect as the
invalid or legally unenforceable  provision, and the remainder of this Agreement
will be deemed modified to conform thereto and will remain in effect.

         7.5  Lifestream may assign its rights and  responsibilities  under this
Agreement in whole or in part; provided, however, in the event the parties enter
into an OEM agreement as  contemplated  by ss.2.2 above,  all issues relating to
assignment  of  rights  under the OEM  Agreement  will be  addressed  by the OEM
Agreement.

         7.6 Polymer may not assign or otherwise  transfer  the License  granted
under this Agreement except by transfer to a successor corporation through

                                        6

<PAGE>

merger or acquisition of Polymer, and Polymer may not sublicense its rights
except as provided in this Agreement.

         7.7 This Agreement will be binding upon and inure to the benefit of the
parties and their respective heirs, successors, and permitted assigns.

         IN WITNESS WHEREOF,  the parties hereto have executed this Agreement in
duplicate,  each of which  constitutes  an  original,  to be effective as of the
latest year and date indicated below.

                           By:  /s/ Robert Huffstodt           Date:  11/12/04
                                --------------------                  --------
                           Polymer Technology Systems, Inc.
                           By: Robert Huffstodt
                           Title: President

                           By:   /s/ Christopher Maus          Date:  11/16/04
                                 --------------------                 --------
                           Lifestream Technologies, Inc.
                           By: Christopher Maus
                           Title: President

                                        7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}]]